T-Cell Acute Lymphoblastic Leukemia

59

Pipeline Programs↗

15

Active Trials↗

33

Companies Involved↗

T-cell acute lymphoblastic leukemia is a moderately active landscape with 59 programs across 33 companies. The most active players are Ascentage Pharma Group Inc., Hebei Senlang Biotechnology Inc., Ltd., Merck & Co.. 1 therapy is approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

22/100

Mech. Concentration

18/100

Completion Rate

56/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Ascentage Pharma Group Inc.

2 programs

Hebei Senlang Biotechnology Inc., Ltd.

1 program

Merck & Co.

1 program

Sanofi

1 program

Arog Pharmaceuticals, Inc.

1 program

Amgen

4 programs

Pipeline

Programs by Phase

Preclinical

No programs

Phase 18

Fludarabine

Sanofi

G-CSF

Arog Pharmaceuticals, Inc.

CD5 CART

Beijing Boren Hospital

Lisaftoclax

Ascentage Pharma Group Inc.

Pelcitoclax

Ascentage Pharma Group Inc.

Phase 236

Alemtuzumab

Genzyme, a Sanofi Company

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Blinatumomab

Amgen

Daratumumab

Johnson & Johnson

Denileukin Diftitox

Eisai

Phase 314

Nelarabine

Novartis

Etoposide

Avyxa

Cytarabine

Teva

Leucovorin Calcium

Eastern Cooperative Oncology Group

Cyclophosphamide

Baxter Healthcare Corporation

Approved1

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Analysis

Modality Breakdown

66%

Small molecule

39 of 59 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 97% of 64 pipeline programs.

Analysis

Trial Status

25

clinical trials

Recruiting9 · 36%

Completed5 · 20%

Active, not recruiting4 · 16%

Terminated3 · 12%

Not yet recruiting2 · 8%

Withdrawn1 · 4%

Other1 · 4%

Clinical Trials

Trial Activity

25 trials

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00501826·160 enrolled

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06390319·100 enrolled

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06561074·22 enrolled

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

Recruiting·SWOG Cancer Research Network·Phase 1/2·NCT04315324·67 enrolled

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Recruiting·WWugen, Inc.·Phase 2·NCT06514794·125 enrolled

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

Recruiting·EEssen Biotech·Phase 1/2·NCT06420076·60 enrolled

NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia

Recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1·NCT05277753·10 enrolled

Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies

Recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1·NCT05995028·30 enrolled

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT04033302·30 enrolled

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05268003·26 enrolled

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02112916·847 enrolled

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03808610·50 enrolled

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Active, not recruiting· Beam Therapeutics logo

Beam Therapeutics·Phase 1/2·NCT05885464·5 enrolled

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07428486·24 enrolled

A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07678307·18 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)